tbuckley/cabot-search huggingface dataset:
PDTM-05. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG
Authors: Nundia Louis, Lihua Zou, Dusten Unruh, Patrick A. Ozark, Andrea Piunti, Vera Gorbunova, Xingyao He, Hiroaki Katagi, Daniel Gryzlo, Ali Zhang, Amanda M. Saratsis, Kathryn Laurie, Rishi Lulla, Jason Fangusaro, Craig Horbinski, Stewart Goldman, C David James, Ali Shilatifard, Rintaro Hashizume
Journal: Neuro-Oncology (2018)

Focal radiation therapy has long been and remains the only treatment option for diffuse intrinsic pontine glioma (DIPG). However, all patients show evidence of disease progression within months of completing radiation therapy (RT). Since chemotherapy does not provide significant outcome improvement, it is crucial to find a suitable radiosensitizer. Our research has shown that the JMJD3 demethylase inhibitor, GSK-J4, exerts potent anti-tumor activity on DIPG cells while restoring methylation. Our aim is to We hypothesized that GSK-J4 may inhibit radiation-induced DNA repair, making it a potential radiosensitizer. RNA sequencing (RNA-Seq) was used to analyze gene expression changes by GSK-J4 in DIPG cells. ATAC-seq was conducted to determine chromatin accessibility in DIPG cells treated with GSK-J4. We evaluated DNA damage repair using DNA repair assay and immunocytochemistry of DSB markers γH2AX and 53BP1. Western blotting and quantitative PCR (qPCR) were conducted to evaluate differential expression of mRNA and proteins involved in DNA DSB repair. In vivo response to radiation monotherapy and combination of RT + GSK-J4 were measured by animal survival studies. RNA-Seq and qPCR show that GSK-J4 significantly reduces DNA DSB repair genes in DIPG cells. ATAC-seq results reveal that GSK-J4 modifies DNA accessibility to regulate expression of DNA repair genes. Immunocytochemistry results support that GSK- J4 sustains high levels of γH2AX and 53BP1 in irradiated DIPG cells, thereby inhibiting DNA DSB repair. DNA repair assay demonstrate that GSK-J4 inhibits DNA damage repair via the homologous recombination pathway. Western blotting revealed that GSK-J4 causes a sustained level of phosphorylated Rad50 and gH2AX in irradiated DIPG cells. In vivo studies revealed increased survival of animals treated with combination therapy compared to monotherapy. These results highlight GSK-J4 as a potential radiosensitizer in DIPG treatment.
Diseases of the Nose, Throat and Ear. For Practitioners and Students.
Journal: JAMA (1924)

In this work the author has revised and elaborated on a previous textbook of diseases of the nose, throat and ear. The material is well organized, being divided into six sections, each one being edited by a specialist in that particular field. It is a clear, concise, readable and up-to-date book. The type is a trifle small, but the paper used is very good. The illustrations, of which twelve are in color, comprise anatomy, dissections, operations and schematic drawings. The operative technic for the more common ear, nose and throat conditions is taken up in considerable detail. Endoscopic technic, however is scarcely treated. On the whole, it is a delightful and very welcome book.
HIV
Authors: Roberto Manfredi
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rapport terminal
Authors: E.J. Anthony, G.W. Arendsen Hein, Dorothy W. Baruch, R. Battegay, Cornelius Beukenkamp, Åke Bjerstedt, Nathan Blackman, Curt Boenheim, Rachel B. Bross, Martha Brunner-Orne, José Angel Bustamante, Udo Derbolowsky, R.S. Drews, G. Egan, I. Frost, Henry Ezriel, C.M. Fleming, Hellmuth Freyberger, D. Fuchs-Kamp, H. Gastager, Henry Raphael Gold, Henry Greenbaum, S. Haddenbrock, Angela Hefferman, Thomas Hora, Asya L. Kadis, Berthold Kihn, F. Knobloch, D. Langen, Karl Hermann Lukas, Michael M. Miller, Theresa G. Muller, Jean Oury, Walter Zenner, Helmut Paul, Hertha Riese, Stefan de Schill, P.-B. Schneider, M. Barrelet, P. Jordi, R. Delaloye, Paul Senft, Gerdhild von Staabs, Mark Stern, Herbert Suchanek-Fröhlich, J. Wilder, Alexander Wolf, Emanuel K. Schwartz, Isidore Ziferstein, Manfred in der Beeck, Jack D. Krasner, G.A. Leutz, Margaret Naumburg, Janet Caldwell, Louis R. Ormont, G. Stürup, Ernst von Xylander
Journal: Psychotherapy and Psychosomatics (1959)
Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia
Authors: Robin Emsley, Jonathan Rabinowitz, Rossella Medori
Journal: American Journal of Psychiatry (2006)

Objective: The authors examined early onset of antipsychotic action and early prediction of nonresponse to antipsychotics in patients with first-episode schizophrenia. Method: Time to clinical response (≥20% improvement in total score on the Positive and Negative Syndrome Scale [PANSS]) was determined in 522 participants in a randomized, controlled trial comparing risperidone and haloperidol. Median treatment length was 206 days. Results: Clinical response was achieved in 77% (N=400) of subjects. Among these patients, clinical response was achieved in 23.3%, 23.3%, 18.5%, and 12.5% at weeks 1, 2, 3, and 4, respectively, after treatment initiation. However, in 22.5% of patients, response was not achieved until after 4 weeks, and in 11.2%, it was not achieved until after 8 weeks. In 45% of patients, response was achieved with a dose of 1–2 mg/day, in 27% with 3 mg/day, in 17% with 4 mg/day, and in the remaining 11% with higher doses. Improvement in the PANSS total score of at least 30%, 40%, and 50%, respectively, were achieved by 63.0%, 44.8%, and 27.5% of patients. Conclusions: Time to antipsychotic response varied widely, suggesting that, in first-episode schizophrenia, longer treatment trials may be necessary.
Grow Thin on Good Food.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reproductive Impairment in the Florida Panther: Nature or Nurture?
Authors: Charles F. Facemire, Timothy S. Gross, Louis J. Guillette
Journal: Environmental Health Perspectives (1995)

Many of the remaining members of the endangered Florida panther (Felis concolor coryi) population suffer from one or more of a variety of physio- logical, reproductive, endocrine, and immune system defects including congenital heart defects, abnormal sperm, low sperm density, cryptorchidism, thyroid dysfunction, and possible immunosuppression.Mercury contamination, determined to be the cause of death of a female panther in 1989, was presented as the likely cause of thyroid dysfunction.As genetic diversity in the species was less than expected, all of the other abnor- malities have been attributed to inbreeding.However, exposure to a variety of chemical compounds, especially those that have been identified as environmental endocrine disrupters (including mercury, p,p'-DDE, and polychlorinated biphenyls), has elicited all of the listed abnormalities in other species.A number of these contaminants are present in South Florida.An exposure pathway has been identified, and evidence presented in this paper, including the fact that there appears to be no significant difference between serum estradiol levels in males and females, suggests that many male panthers may have been demasculinized and feminized as a result of either prenatal or postnatal exposure.Thus, regardless of the effects of inbreeding, current evidence seems to indicate that environmental contaminants may be a major factor contributing to reproductive impairment in the Florida panther population.
A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons
Authors: Theron A. Russell, Masafumi Ito, Mika Ito, Richard N. Yu, Fred A. Martinson, Jeffrey Weiss, J. Larry Jameson
Journal: Journal of Clinical Investigation (2003)

Familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant disorder caused by mutations in the arginine vasopressin (AVP) precursor. The pathogenesis of FNDI is proposed to involve mutant protein–induced loss of AVP-producing neurons. We established murine knock-in models of two different naturally occurring human mutations that cause FNDI. A mutation in the AVP signal sequence [A(–1)T] is associated with a relatively mild phenotype or delayed presentation in humans. This mutation caused no apparent phenotype in mice. In contrast, heterozygous mice expressing a mutation that truncates the AVP precursor (C67X) exhibited polyuria and polydipsia by 2 months of age and these features of DI progressively worsened with age. Studies of the paraventricular and supraoptic nuclei revealed induction of the chaperone protein BiP and progressive loss of AVP-producing neurons relative to oxytocin-producing neurons. In addition, Avp gene products were not detected in the neuronal projections, suggesting retention of WT and mutant AVP precursors within the cell bodies. In summary, this murine model of FNDI recapitulates many features of the human disorder and demonstrates that expression of the mutant AVP precursor leads to progressive neuronal cell loss.
Abstract 3005: High density lipoprotein mimics inhibit prostate cancer exosome-mediated communication with myeloid cells
Authors: Stephen E. Henrich, Kaylin M. McMahon, Michael P. Plebanek, C. Shad Thaxton
Journal: Cancer Research (2019)

Abstract Introduction: Exosomes are 30-150 nm membrane-bound vesicles that mediate intercellular communication and are secreted in abundance by neoplastic cells. Tumor-derived exosomes are capable of transmitting pro-malignant signals to target cells at local or distant sites to enhance tumor invasiveness and promote metastasis. A sub-set of this pro-malignant intercellular communication is dependent upon target cell cholesterol homeostasis. Here, we show that prostate cancer exosome communication with myeloid cells can be inhibited by treatment with high density lipoprotein mimetic nanoparticles (HDL NPs), which reduce cholesterol in myeloid cells in a targeted fashion. Methods: Exosomes were isolated by ultracentrifugation of conditioned media from enzalutamide resistant CWR-R1 cells and used for all experiments. In vitro assays were conducted using murine bone marrow macrophages obtained from culture of total murine bone marrow in M-CSF for 7 days. Confocal microscopy and flow cytometry were used for in vitro and in vivo uptake assays. Osteoclastogenesis assays were performed using a commercially available TRAP staining kit (Sigma-Aldrich). NF-kB signaling experiments were performed using a reporter human monocyte cell line (THP1-Dual). HDL NPs were synthesized using 5 nm gold nanoparticle templates, apolipoprotein A-1, and phospholipids. Results: HDL NPs were found to inhibit the cellular uptake of prostate cancer exosomes in mouse bone marrow macrophages in vitro. Furthermore, HDL NPs inhibited exosome-induced osteoclastogenesis and exosome-induced monocyte NF-kB signaling. Finally, HDL NP-mediated inhibition of exosome communication was found to be dependent upon scavenger receptor type B-1 (SR-B1). SR-B1 was shown to be expressed ubiquitously in mouse bone marrow macrophages; and HDL NPs were unable to inhibit exosome communication in bone marrow macrophages derived from SR-B1-/- mouse bone marrow. Conclusion: These data demonstrate that HDL NPs inhibit prostate cancer exosome communication with murine myeloid cells, as evidenced by cellular uptake, osteoclastogenesis, and NF-kB signaling. Moreover, SR-B1 is required for HDL NP inhibition of PCa exosome communication. In sum, these results indicate that target cell cholesterol homeostasis may be important for exosome-mediated signaling in prostate cancer, particularly in immune cells and in the bone microenvironment, and that HDL NPs are potent inhibitors of PCa exosome-mediated signaling. Citation Format: Stephen E. Henrich, Kaylin M. McMahon, Michael P. Plebanek, C. Shad Thaxton. High density lipoprotein mimics inhibit prostate cancer exosome-mediated communication with myeloid cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3005.
This Week in &lt;emph&gt;JAMA&lt;/emph&gt;
Journal: JAMA (2010)

A Piece of My Mind" 'My belief is we all die when our time is up.I'm not afraid of death,' he said.'We all have to die sometime.'" From "The Changing of the Seasons." SEE PAGE 493 Medical News & PerspectivesTo fulfill new federal requirements aimed at curbing opioid-related overdose deaths, industry groups have proposed additional training of clinicians who prescribe these drugs.But the proposal has met with resistance.
Onychectomy
Authors: K. P. A. Taylor
Journal: JAMA (1969)

<h3>To the Editor:—</h3> Concerning the discussion, "Obloquy on Onychectomy" (<b>207</b>:1358, 1969), optimism is warranted for the successful permanent removal of the great toe nail. The method is described (<i>Amer J Surg</i><b>17</b>:8, 1935). Complete saucerization of tissue overlying the nail beds and margins, curettage of the radix, and the electrocauterization of the radix particularly at its corners assure nonregeneration of the nail. Spicules of nail regrew in about 2% of nails so treated. They were avulsed and their source recauterized, with no subsequent regrowth while under observation.
National Cancer Institute Monograph 41, March 1975 “Third National Cancer Survey: Incidence Data” Editors: Sidney J. Cutler and John L. Young, Jr.
Journal: JNCI Journal of the National Cancer Institute (1975)

National Cancer Institute Monograph 41, March 1975 “Third National Cancer Survey: Incidence Data” Editors: Sidney J. Cutler and John L. Young, Jr. Get access JNCI: Journal of the National Cancer Institute, Volume 55, Issue 3, September 1975, Page 738, https://doi.org/10.1093/jnci/55.3.738-c Published: 01 September 1975
AMA-RPS Acts on Resident Concerns
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unreviewed Reports
Authors: P Molitor, A Warrens
Journal: BMJ (1985)

Unreviewed ReportsAcute orchitis associated with hepatitis B infection A 38 year old man presented with a one week history of malaise and increasing jaundice.Two hours before presentation he developed right testicular pain and swelling.He was icteric with bilateral testicular tenderness.Orchitis was diagnosed clinically and hepatitis B confirmed by serology.Viral orchitis is commonly associated with mumps but has also been linked with other viral conditions.These associations were established from clinical laboratory or epidemio- logical evidence.Hepatitis B should be added to the list of viral conditions causing orchitis.-
Magnet for Removing Tube from Larynx.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
D.D.T. in the environment.
Journal: BMJ (1969)

RDICTSOU to the virus.The findings of H. L. Moses and colleagues,1 however, complicate the issue: only four out of 14 continuous suspension cultures of leucocytes from nine cases contained Epstein-Barr virus, but all contained reticular arrays of much smaller virus-like particles.Similar small particles have been seen in lymphomas and in tumours induced by Rous sarcoma virus.Viruses like the Epstein-Barr organism have been found in cells cultured from lymphoid tissue of cancer patients,21 in peripheral leucocytes from cases of myeloblastic and lymphoblastic leukaemia,2' 23 and from apparently healthy people.24Indeed, Moses and colleagues"7 state that the fre- quency with which Epstein-Barr-like viruses are found in cell lines from cases of infectious mononucleosis is not greater than the frequency with which they are found in similar cell lines from patients with leukaemia or other forms of cancer.Clearly infection with a virus like the Epstein-Barr organism is common, and it is sometimes associated with infectious mononucleosis.Infection probably often persists in a latent form, and whether the possible " helper virus "seen by Moses and colleagues'7 plays a part is unknown.An important question is whether these viruses or the Epstein- Barr virus itself are oncogenic.There are certainly some
THE SCHWANN CELL
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal of Pharmacy and Pharmacology, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal